drugset / Trial / NCT07099157
Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster
Phase 4
Recruiting
140 enrolled
Peking University Third Hospital
Air Force Military Medical University, China · collabBeijing Hospital of Traditional Chinese Medicine · collabPeking University First Hospital · collabXuanwu Hospital, Beijing · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30. Secondary objectives: Compare NPRS at Day 3/Day 7/Day 14/Day 90, time to lesion resolution, Postherpetic Neuralgia (PHN) incidence, and safety.
Timeline
- Start
- 2025-08-25
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brivudine | Small molecule | 125 mg | — |
| Comparator | Famciclovir | Small molecule | — | Oral |